Advertisement
Advertisement
MGNX
MacroGenics, Inc.
1.80
USDSponsored
+0.10
+6.18%
Feb 06, 15:55 UTC -5
Closed
After-Market
1.75
-0.05
-2.77%
MGNX Earnings Reports
Positive Surprise Ratio
MGNX beat 17 of 40 last estimates.
43%
Next Report
Date of Next Report
Feb 19, 2026
Estimate for Q4 25 (Revenue/ EPS)
$23.10M
/-$0.29
Implied change from Q3 25 (Revenue/ EPS)
-68.29%
/-207.41%
Implied change from Q4 24 (Revenue/ EPS)
+19.34%
/+16.00%
MacroGenics, Inc. earnings per share and revenue
On Nov 12, 2025, MGNX reported earnings of 0.27 USD per share (EPS) for Q3 25, beating the estimate of -0.50 USD, resulting in a 153.84% surprise. Revenue reached 72.84 million, compared to an expected 14.99 million, with a 385.79% difference. The market reacted with a +8.84% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analysts forecast an EPS of -0.29 USD, with revenue projected to reach 23.10 million USD, implying an decrease of -207.41% EPS, and decrease of -68.29% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Phibro Animal Health Corporation Class A
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.68
Actual
$0.87
Surprise
+27.30%
Aurora Cannabis Inc. Common Shares
Report Date
Feb 04, 2026 For Q3 26
Estimate
$0.21
Actual
$0.12
Surprise
-42.72%
High Tide Inc. Common Shares
Report Date
Jan 29, 2026 For Q4 25
Estimate
$0.00
Actual
-$0.56
Surprise
0.00%
Stryker Corporation
Report Date
Jan 29, 2026 For Q4 25
Estimate
$4.43
Actual
$4.47
Surprise
+0.69%
Boston Scientific Corp.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.78
Actual
$0.80
Surprise
+1.61%
ResMed Inc.
Report Date
Jan 29, 2026 For Q2 26
Estimate
$2.75
Actual
$2.81
Surprise
+2.15%
GE HealthCare Technologies Inc. Common Stock
Report Date
Feb 04, 2026 For Q4 25
Estimate
$1.42
Actual
$1.44
Surprise
+0.96%
Envista Holdings Corporation Common stock, $0.01 par value per share
Report Date
Feb 05, 2026 For Q4 25
Estimate
$0.32
Actual
$0.38
Surprise
+15.43%
Prestige Consumer Healthcare Inc.
Report Date
Feb 05, 2026 For Q3 26
Estimate
$1.15
Actual
$1.13
Surprise
-1.36%
Haemonetics Corporation
Report Date
Feb 05, 2026 For Q3 26
Estimate
$1.26
Actual
$1.31
Surprise
+3.75%
FAQ
What were MacroGenics, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, MacroGenics, Inc. reported EPS of $0.27, beating estimates by 153.84%, and revenue of $72.84M, 385.79% above expectations.
How did the market react to MacroGenics, Inc.'s Q3 2025 earnings?
The stock price moved up 8.84%, changed from $1.47 before the earnings release to $1.60 the day after.
When is MacroGenics, Inc. expected to report next?
The next earning report is scheduled for Feb 19, 2026.
What are the forecasts for MacroGenics, Inc.'s next earnings report?
Based on 9
analysts, MacroGenics, Inc. is expected to report EPS of -$0.29 and revenue of $23.10M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement